Valuation: Alzamend Neuro, Inc.

Market Cap 63.46L 56.4L 52.57L 47.93L 90.4L 61Cr 91.27L 6.37Cr 2.47Cr 31Cr 2.38Cr 2.33Cr 100.16Cr P/E 2027 *
-1.3x
P/E 2028 * -1.57x
Enterprise Value 63.46L 56.4L 52.57L 47.93L 90.4L 61Cr 91.27L 6.37Cr 2.47Cr 31Cr 2.38Cr 2.33Cr 100.16Cr EV / Sales 2027 *
-
EV / Sales 2028 * -
Free-Float
97.34%
Yield 2027 *
-
Yield 2028 * -
1 day+4.18%
1 week-24.73%
Current month-20.81%
1 month-16.30%
3 months+22.32%
6 months+34.31%
Current year-24.73%
1 week 1.2
Extreme 1.2
1.92
1 month 1.2
Extreme 1.2
1.95
Current year 0.84
Extreme 0.84
2.54
1 year 0.84
Extreme 0.84
2.68
3 years 0.84
Extreme 0.84
318.6
5 years 0.84
Extreme 0.84
4,562.86
10 years 0.84
Extreme 0.84
45,292.48
Manager TitleAgeSince
Chief Executive Officer 50 20/11/2018
Director of Finance/CFO 64 05/08/2022
General Counsel 57 01/05/2019
Director TitleAgeSince
Chairman 56 26/02/2016
Chairman 57 01/06/2021
Director/Board Member 50 01/09/2020
Date Insider Type Main position Quantity % Market Cap. Importance
26/08/26 Sell

Founder

-2,000 0.0417%
26/08/26 OtherCompany 0 0% -
31/07/26 FreeCompany 7,500 0.1565%
Change 5-day change 1-year change 3-year change Capi.($)
+4.18%-24.73%-44.08%-99.57% 63.46L
+4.16%+3.04%+49.37%+94.17% 7.44TCr
-3.11%-2.32%+23.28%+77.03% 5.93TCr
+0.89%-0.77%+5.80%+32.89% 4.71TCr
-0.96%-6.11%+26.70%+31.24% 4.29TCr
+0.36%+3.39%+350.59%+646.53% 4.41TCr
-0.20%-0.53%+6.84%+99.07% 4.08TCr
-0.54%+2.93%+9.50%+50.41% 3.08TCr
-2.68%+5.11%+33.11%+19.50% 2.93TCr
+2.33%-8.58%-24.55%+340.08% 2.37TCr
Average +0.44%-3.35%+43.66%+129.14% 3.92TCr
Weighted average by Cap. +0.24%-0.40%+58.36%+145.81%

Financials

2027 *2028 *
Net sales - -
Net income -1.08Cr -95.99L -89.48L -81.56L -1.54Cr -104Cr -1.55Cr -11Cr -4.2Cr -53Cr -4.05Cr -3.97Cr -170.46Cr -1.08Cr -95.99L -89.48L -81.56L -1.54Cr -104Cr -1.55Cr -11Cr -4.2Cr -53Cr -4.05Cr -3.97Cr -170.46Cr
Net Debt - -
Logo Alzamend Neuro, Inc.
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.
Employees
5
Date Price Change Volume
02/26/02 $1.370 +4.18% 2,35,963
01/26/01 $1.315 -23.99% 1,50,749
30/26/30 $1.730 -4.95% 21,693
29/26/29 $1.820 +5.20% 49,609
28/26/28 $1.730 -5.46% 83,827
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.370USD
Average target price
26.00USD
Spread / Average Target
+1,797.81%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALZN Stock